MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Ketamir-2 Results; DEA Confirms Not Controlled Substance

summarizeSummary

MIRA Pharmaceuticals announced positive unblinded Phase 1 results for Ketamir-2, showing strong safety and a favorable pharmacokinetic profile, alongside a crucial DEA ruling that the drug is not a controlled substance.

check_boxKey Events

• Positive Unblinded Phase 1 Results

  Ketamir-2 showed strong safety and tolerability in 57 healthy volunteers, with fewer adverse events reported in the treatment group compared to placebo.

• Favorable Pharmacokinetics

  The drug demonstrated rapid oral absorption, dose-proportional exposure, and a half-life supporting potential once-daily administration.

• DEA Not a Controlled Substance

  The U.S. Drug Enforcement Administration determined that Ketamir-2 is not classified as a controlled substance, significantly de-risking its regulatory and commercial path.

• Advancing to Phase 2a

  The company is preparing for Phase 2a clinical protocol submission to the FDA for evaluation in chemotherapy-induced peripheral neuropathy (CIPN).

auto_awesomeAnalysis

This filing provides critical positive unblinded Phase 1 clinical trial results for Ketamir-2, demonstrating a strong safety profile with fewer adverse events than placebo, and a pharmacokinetic profile supporting once-daily dosing. The most significant update is the U.S. DEA's determination that Ketamir-2 is not classified as a controlled substance, which substantially de-risks the drug's commercial pathway and broadens its market potential. This positive development is particularly important for a company that recently issued a going concern warning.